Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Momenta Jumped Higher Today

By Brian Orelli, PhD - Jun 15, 2020 at 2:08PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Positive phase 2 clinical trial data puts the biotech's lead drug candidate on a good path forward.

What happened

Shares of Momenta Pharmaceuticals (MNTA) were up by about 15% at 2:04 p.m. EDT Monday after the biotech released positive results from its phase 2 clinical trial of nipocalimab as a treatment for generalized myasthenia gravis.

So what

Generalized myasthenia gravis is a chronic autoimmune neuromuscular disease that causes the immune system to creates antibodies that block muscle receptors responsible for getting signals from nerve cells. Nipocalimab is designed to block those deleterious antibodies.

The clinical trial tested four different dosing regimens and found that 52% of patients treated with nipocalimab improved at least 2 points on the Myasthenia Gravis Activities of Daily Living scale for at least four consecutive weeks, compared to just 15% of patients taking a placebo. As expected, patients with larger reductions in the antibodies that cause the disease had better improvements on the scale.

Doctor talking to a patient

Image source: Getty Images.

Now what

The study is still ongoing with patients being treated for 16 weeks. Final data is expected in the fourth quarter, but it seems likely that it'll show the drug is working. Momenta is already planning to start a phase 3 clinical trial next year.

Beyond generalized myasthenia gravis, Momenta is testing nipocalimab against two other autoimmune diseases caused by deleterious antibodies: warm autoimmune hemolytic anemia and hemolytic disease of the fetus and newborn. Those programs are somewhat de-risked thanks to the positive results so far for the treatment in generalized myasthenia gravis, although Momenta will still need to show that reducing the harmful antibodies in question can reverse the symptoms of those diseases.

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool recommends Momenta Pharmaceuticals. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Momenta Pharmaceuticals, Inc. Stock Quote
Momenta Pharmaceuticals, Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/14/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.